Cytori Therapeutics, Inc. (NASDAQ: CYTX) is committed to becoming the global leader in regenerative medicine. The company focuses on providing patients with new options for reconstructive and aesthetic surgery, developing treatments for cardiovascular disease, and banking adipose-derived, adult stem and regenerative cells (ADRCs). To meet its objective, Cytori developed Celution® Technology to separate and concentrate a patient’s own ADRCs for delivery back to the same patient in a single surgical procedure. For further information, visit the Company’s web site at www.cytoritx.com.
- 17 years ago
QualityStocks
Cytori Therapeutics, Inc. (NASDAQ: CYTX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – GlobalTech Corporation (OTCID: GTLK) Posts 23% Revenue Growth in Q2 2025 on Strong Telecom Performance
GlobalTech (OTCID: GTLK), a technology holding company specializing in artificial intelligence and big data solutions,…
-
QualityStocksNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Narrows Q2 Loss 66% as E-Commerce Growth Offsets Healthcare Headwinds
NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company in healthcare and technology,…
-
QualityStocksNewsBreaks – Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Stands Distinct Against Walker Lane Backdrop
Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is positioned as investors view the Walker Lane corridor in…